Clinical Trials
Sanofi and Regeneron report positive Phase IIb trial results of dupilumab in asthma patients
Sanofi and Regeneron Pharmaceuticals have reported positive results from the interim analysis of a dose-ranging Phase IIb trial of dupilumab, a fully-human monoclonal antibody, in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is directed against the...
Clinical Trials
Sarepta doses first patient in eteplirsen trial to treat duchenne muscular dystrophy
US-based Sarepta Therapeutics has started dosing patients in a clinical trial of its lead exon-skipping therapeutic candidate eteplirsen to treat Duchenne muscular dystrophy (DMD). The open-label trial (Study 204) will be carried out in DMD patients...
Clinical Trials
TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative,...
Clinical Trials
FDA Approves Addition to CIALIS® (tadalafil) Product Label
Eli Lilly and Company announced the U.S. FDA approved a product label addition for CIALIS to include data from a 26-week study that showed CIALIS 5 mg for once daily use started in combination with finasteride significantly improved the...
Clinical Trials
The Netherlands-based company Prosena has begun the submission process for drisapersen, its treatment for Duchenne muscular dystrophy (DMD).
The news is a remarkable turnaround for the drug, which had looked doomed to failure just a few months ago. In January this year, GlaxoSmithKline returned the rights to the drug following failure in Phase 3 trials. ...
Clinical Trials
Oramed recruits patients to study orally ingestible insulin capsule
Oramed Pharmaceuticals has started recruiting patients for a new clinical trial of ORMD-0801, an orally ingestible insulin capsule, for patients with type 1 diabetes mellitus (T1DM) in Israel. The company is also conducting ORMD-0801 US...
Clinical Trials
DiaMedica completes enrollment in DM199 single ascending dose diabetes study
Clinical stage biopharmaceutical company DiaMedica has completed enrollment of type 2 diabetic patients in the DM199 single ascending dose (SAD) clinical study. The randomized study is designed to assess three dose levels each in type...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















